about
Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review.Low PKCĪ± expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome.New methodologic approaches for immunophenotyping acute leukemias.Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia.Spinal cord injury without radiographic abnormalities.Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping.Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL.Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in childrenUnrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemiaA Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute LeukemiaMLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP studyImmunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemiaDonor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantationIdentification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaAdvanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?Trisomy 7 and deletion of the 9p21 locus as novel acquired abnormalities in a case of pediatric biphenotypic acute leukemiaThe presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocolsCerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemiaFlow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemiaGenetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing
P50
Q30979525-505C5C2E-A8B3-47F7-AD47-5BFD87511192Q34221792-053E0519-ACFC-456E-ADC6-3C41DFE980D8Q34309130-12FF850B-2C47-49B6-B1C0-EBBC7836AA41Q40316983-E7E7D1AA-58C7-4192-A4D0-D84AB1717B72Q40799494-35E326B6-B38C-4E8A-90C7-E9836C829BDEQ40910460-EC8B3965-17D3-4EDC-B504-D5B3B663FD5CQ42847773-17C607C5-E788-4ECC-BDD9-F996FEE5BF07Q43266780-7CD6A346-5E7D-4544-80E8-ACFC9B41DDF7Q47199612-041C9D00-44B4-4A21-B105-F40C55265E6DQ47976103-42CD52B2-6BB0-4E04-83EB-988C9CB5B11FQ48159392-C76D3082-A4D1-43ED-9957-03F58519CE43Q48186727-D5A7B1A9-AD38-42F3-88FC-CD57A3010611Q49023149-C0768621-FE7F-4065-A315-607321DC0091Q50095719-DB76F81C-59D7-4B79-8B0C-2DA3CB6FBB40Q52689080-DC960622-4F3F-42E1-8727-E3BB1CCF74D8Q52803502-8D141D50-DF6A-47F9-BB3E-5FF203E6410BQ52875100-ADB2A8A8-F777-4D7C-9E8F-219F08253D93Q52927258-D5E9BD80-DDF9-4EB5-8786-18E0AB7191BCQ56379419-04616CD1-1901-44F0-A5C2-43BCC303DE40Q57801274-E9126470-FBE6-4F09-997C-DECEE96E0D69Q60146455-16A1AD32-3FC8-4BD0-97DE-0445E3C9F70DQ60170373-8CA38CFE-9DC6-4043-8BC0-2E12E55DE69EQ60170385-6CC24D8C-1AAC-49ED-9553-9AB440C22B7FQ63257363-F26995F6-7B6F-4ED4-823E-99129E24F421Q82616567-5CC954C0-6475-4EC5-968F-711E1F93F33BQ82860005-02929432-67AE-4050-A949-E38ABA2B1E02Q83277744-3C327C83-FA48-4BF3-9960-89E4BA45330CQ89230110-FFACAD57-4DC6-4907-A737-77588A2A3FFEQ90280175-9F17B639-0AAD-48BF-BC05-DE04FE6AF723Q90607704-FAFBB3C1-9F6B-4EA8-8CDC-0D3868FCCFE2Q91296771-5F9419D9-3B7E-4E14-A23C-8391CA6CB290Q91326518-857E1C1B-80CF-43FF-B2F3-006AD65B75D5
P50
description
researcher
@en
name
Barbara Buldini
@en
Buldini B
@nl
type
label
Barbara Buldini
@en
Buldini B
@nl
altLabel
Buldini B
@en
prefLabel
Barbara Buldini
@en
Buldini B
@nl
P106
P31
P496
0000-0001-7285-2390